GlassScriptPhysician profile
Amy Rae Carroll
NPI 1659575256
$4,593.63
in general payments reported to CMS, 2019-2025
40 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,014 · 2020: $474 · 2021: $391 · 2022: $474 · 2023: $624 · 2024: $837 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,240.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $742.26 | 2019-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $664.44 | 2019-2025 | Lynparza, Tagrisso |
| Merck Sharp & Dohme LLC | $596.47 | 2019-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Seagen INC. | $398.08 | 2022-2023 | Tivdak |
| Tesaro, INC. | $280.94 | 2019 | |
| Pfizer INC. | $249.45 | 2024-2025 | |
| Eisai INC. | $223.03 | 2019-2025 | |
| Clovis Oncology, INC. | $220.09 | 2019-2022 | |
| Lsi Solutions INC | $139.71 | 2023-2025 | Fornisee, Ti-Knot, Running Device |
| Abbvie INC. | $113.35 | 2019-2025 | |
| Davol INC. | $89.04 | 2019-2024 | Arista Ah Flexitip |
| Astellas Pharma US INC | $82.91 | 2020-2025 | Veozah |
| Myriad Genetic Laboratories, INC. | $71.00 | 2020-2021 | |
| Fennec Pharmaceuticals, INC. | $67.66 | 2024-2025 | Fyarro, Pedmark |
| Mimedx Group, INC. | $58.64 | 2024-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.